PMID- 25829187
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20220330
IS  - 0048-7449 (Print)
IS  - 0048-7449 (Linking)
VI  - 66
IP  - 4
DP  - 2015 Mar 31
TI  - Elevated serum levels of macrophage migration inhibitory factor and stem cell 
      growth factor beta in patients with idiopathic and systemic sclerosis associated 
      pulmonary arterial hypertension.
PG  - 270-6
LID - 10.4081/reumatismo.2014.774 [doi]
AB  - Pulmonary arterial hypertension (PAH) can be idiopathic or secondary to 
      autoimmune diseases, and it represents one of the most threatening complications 
      of systemic sclerosis (SSc). Macrophage migration inhibitory factor (MIF) is a 
      pleiotropic cytokine with proinflammatory functions that appears to be involved 
      in the pathogenesis of hypoxia-induced PH. In SSc patients, high serum levels of 
      MIF have been associated with the development of ulcers and PAH. Stem cell growth 
      factor beta (SCGF beta) is a human growth factor that, together with MIF, is involved 
      in the pathogenesis of chronic spinal cord injury. The aim of our study was to 
      measure serum levels of MIF in patients with idiopathic and SSc-associated PAH. 
      We enrolled 13 patients with idiopathic PAH and 15 with SSc-associated PAH. We 
      also selected 14 SSc patients without PAH and 12 normal healthy controls, matched 
      for sex and age. PAH was confirmed by right hearth catheterism (mPAP>25 mmHg). 
      MIF and SCGF beta levels were measured by ELISA. We found significantly higher 
      circulating levels of MIF and of SCGF beta in patients with idiopathic PAH (P=0.03 
      and P=0.004) and with PAH secondary to SSc (P=0.018 and P=0.023) compared to SSc 
      patients without PAH. Higher levels of MIF were found in those patients with an 
      higher New York Heart Association (NYHA) class (P=0.03). We can hypothesize that 
      MIF and SCGF beta are able to play a role in PAH, both idiopathic or secondary, and 
      in the future they may be evaluated as useful biomarkers and prognostic factors 
      for this serious vascular disease.
FAU - Stefanantoni, K
AU  - Stefanantoni K
AD  - Dipartimento di Medicina Interna e Specialita Mediche, UOC Reumatologia, 
      Universita La Sapienza, Roma. katia.stef@alice.it.
FAU - Sciarra, I
AU  - Sciarra I
FAU - Vasile, M
AU  - Vasile M
FAU - Badagliacca, R
AU  - Badagliacca R
FAU - Poscia, R
AU  - Poscia R
FAU - Pendolino, M
AU  - Pendolino M
FAU - Alessandri, C
AU  - Alessandri C
FAU - Vizza, C D
AU  - Vizza CD
FAU - Valesini, G
AU  - Valesini G
FAU - Riccieri, V
AU  - Riccieri V
LA  - eng
PT  - Journal Article
DEP - 20150331
PL  - Italy
TA  - Reumatismo
JT  - Reumatismo
JID - 0401302
RN  - 0 (Biomarkers)
RN  - 0 (Macrophage Migration-Inhibitory Factors)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*blood/diagnosis/immunology
MH  - Macrophage Migration-Inhibitory Factors/*blood
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Scleroderma, Diffuse/blood
MH  - Scleroderma, Limited/blood
MH  - Scleroderma, Systemic/*blood/diagnosis/immunology
MH  - Sensitivity and Specificity
MH  - Transforming Growth Factor beta/*blood
EDAT- 2015/04/02 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/04/02 06:00
PHST- 2014/06/10 00:00 [received]
PHST- 2015/02/03 00:00 [accepted]
PHST- 2015/01/29 00:00 [revised]
PHST- 2015/04/02 06:00 [entrez]
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.4081/reumatismo.2014.774 [doi]
PST - epublish
SO  - Reumatismo. 2015 Mar 31;66(4):270-6. doi: 10.4081/reumatismo.2014.774.